Sanofi : Dupixent pourra s’attaquer au marché de la COPD
>Résultats positifs de Dupixent dans la COPD - Nous venons d’apprendre les résultats positifs de l’essai évaluant Dupixent dans la bronchite chronique du fumeur (COPD). Du fait des co-morbidités de la pathologie et du nombre d’échec pour les médicaments biologiques dans cette indication, nous voyons ces résultats comme extrêmement positifs pour le groupe. L’ensemble des critères primaires et secondaires ont été atteints dans cet essai avec notamment : i/ une rédu...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.